Results 161 to 170 of about 1,761 (189)
Some of the next articles are maybe not open access.
[Zoster disease after Shingrix vaccination].
Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2021Shingrix is a recombinant adjuvant subunit vaccine. The vaccine is approved in Germany for prevention of zoster manifestation and postherpetic neuralgia in adults aged ≥60 years. In the case of bullous skin lesions after vaccination with Shingrix a zoster disease should be considered.
D, Kohn, T, Wetzig
openaire +1 more source
Shingrix : A New Vaccine for Shingles
2023Therapeutics Letter 114 looks at Shingrix, a new vaccine for shingles. Conclusions: Compared to placebo the Shingrix vaccine reduced the incidence of herpes zoster by 3.26 % (NNV = 31) over 3.5 years in all age groups and reduced the incidence of post-herpetic neuralgia by 0.28% (NNV ≈ 350).
openaire +1 more source
Shingrix for Herpes Zoster: A Review
Skin therapy letter, 2020Herpes zoster (HZ), also known as shingles, results from reactivation of the latent varicella-zoster virus (VZV), which commonly causes chickenpox in childhood. Greater than 90% of adults are infected with this virus, putting them at risk for reactivation. HZ presents as a painful, vesicular rash distributed in a unilateral and dermatomal pattern along
Radhika A, Shah +5 more
openaire +1 more source
Recombinant Zoster Vaccine (Shingrix®): A Review in Herpes Zoster
Drugs & Aging, 2018Shingrix® is a recombinant zoster vaccine (RZV) that contains a varicella zoster virus glycoprotein E antigen and the AS01B adjuvant system. The subunit vaccine is approved for the prevention of herpes zoster (HZ) [EU, USA, Japan, Canada and Australia] and postherpetic neuralgia (PHN) [EU and Australia] in adults aged ≥ 50 years.
openaire +2 more sources
Shingrix: A New Herpes Zoster Vaccine.
P & T : a peer-reviewed journal for formulary managementShingrix, a new vaccine for herpes zoster.
Fraidy, Maltz, Brooke, Fidler
openaire +1 more source
Pityriasis rubra pilaris following Shingrix vaccine: a report of two cases
Clinical and Experimental DermatologyPityriasis rubra pilaris (PRP) is a rare papulosquamous disorder. While PRP has been reported following various vaccinations, no association with the Shingrix vaccine has previously been documented. Here, we present the first two reported cases of PRP following Shingrix vaccination.
Richard Han +4 more
openaire +2 more sources
Hypermetabolic Axillary Lymphadenopathy After Shingrix Vaccination for Varicella Zoster Virus
Clinical Nuclear MedicineAbstract A 67-year-old woman underwent staging 18F-FDG PET/CT scan for recently diagnosed breast cancer. Her scan showed a highly hypermetabolic right breast mass, with ipsilateral hypermetabolic axillary lymph nodes. The contralateral axillary lymph nodes were also enlarged with avid FDG uptake, alongside focal increased uptake in the left ...
Yael, Eshet +3 more
openaire +2 more sources
Recombinant Zoster Vaccine (Shingrix): Real-World Effectiveness in the First 2 Years Post-Licensure
Clinical Infectious Diseases, 2021Hector S Izurieta +2 more
exaly